Shionogi & Co., Ltd.
Public K.K.
Traded as TYO: 4507
OSE: 4507
Nikkei 225 Component
Industry Biotechnology & Pharmaceuticals
Founded Osaka, Japan (March 17, 1878 (1878-03-17))
Founder Gisaburo Shiono, Sr.
Headquarters 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan
Key people
Revenue Increase $ 3.009 billion USD (FY 2012)
(¥ 282.904 billion JPY) (FY 2012)
Increase $709.79 million USD (FY 2012)
(¥ 66.728 billion JPY) (FY 2012)
Number of employees
Consolidated : 6,082
Website Official website
Footnotes / references

Shionogi & Company, Limited (塩野義製薬株式会社 Shionogi Seiyaku Kabushiki Kaisha) is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses Shionogi ("シオノギ").

Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.

In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.

Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.[3]

The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.[4]




  1. "Shionogi Company Profile". Retrieved March 18, 2014.
  2. "Shionogi Annual Report 2013" (PDF). Retrieved March 18, 2014.
  3. "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio". Retrieved 18 March 2014.
  4. "Components:Nikkei Stock Average". Nikkei Inc. Retrieved March 11, 2014.
  5. Perry, Alan. "Sponsor Company Profiles". Retrieved 25 April 2012.

This article is issued from Wikipedia - version of the 10/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.